Diffuse Midline Glioma (H3K27M mutant) in Adult: A Diagnostic Challenge

Sonal Paul, Nitin.M. Gadgil and Chetan Chaudhari
Department of Pathology, Lokmanya Tilak Medical college and General Hospital, Sion, Mumbai

ABSTRACT

Introduction: Diffuse midline glioma (DMG), H3K27M mutant is an infiltrative midline high grade glioma with predominantly astrocytic differentiation and K27M mutation in either H3F3A or HIST1H3B/C.

Case Report: A 45-year-old female presented with complaints of headache and memory loss for 3 months. MRI was suggestive of an infiltrative mass lesion in the quadrigeminal plate cistern suggestive of pineal neoplasm. Squash and histomorphology showed a low-grade astrocytic tumour with infiltrative growth pattern. Microvascular proliferation and necrosis were absent. Immunohistochemistry showed loss of ATRX protein, focal positivity for p53 protein IDH1R132H negativity. On molecular analysis, H3K27M mutation was noted and the case was labelled as DMG H3K27Mmutant (WHO IV)

Conclusion: DMG (H3K27M) is a newly added entity in the WHO 4th revised edition of 2016. It presents with a diagnostic challenge as it has varied histomorphology, not requiring atypia, mitosis, endothelial hyperplasia and necrosis for diagnosis as Grade IV.

Keywords: Adult, Diffuse Midline Glioma, H3K27M Mutation

Introduction
The 2016 WHO Classification has combined histological as well as molecular parameters as a pre requisite before rendering the diagnosis of any CNS tumor as opposed to the earlier classifications which were based primarily on morphology. Revised 2016 WHO Classification has recognized Diffuse midline glioma (DMG) (H3K27M mutant) as a distinct entity corresponding to WHO grade IV. Previously, these cases were classified as brainstem gliomas or Diffuse intrinsic pontine gliomas. They have an aggressive clinical behaviour and distinct molecular features. It is usually seen in children but can also be seen in adults with a median age of 3 years and a slight female predominance.

Case Report
We present a 45-year-old female with complaints of headache and memory loss for 3 months. MRI was suggestive of an infiltrating mass lesion in the quadrigeminal plate cistern suggestive of pineal neoplasm. Squash and histomorphology showed a low-grade astrocytic tumour with infiltrative growth pattern. Nuclear pleomorphism, few large nuclei and calcification were seen. No microvascular proliferation or necrosis was seen. Special stain for reticulin confirmed the nodular architecture. Immunohistochemistry was performed which showed CD34 negativity suggestive of no vascular proliferation. Loss of ATRX protein, focal positivity for p53 protein and IDH1R132H negativity was noted. A diagnosis of pilocytic astrocytoma was considered on the basis of histomorphology and immunohistochemistry.

However, in view of the midline location and aggressive clinical behaviour, a molecular analysis was performed. Template DNA isolated from the tumor cells was amplified via Polymerase Chain Reaction using H3F3A primers flanking a 300-base pair exonal region encoding Lys27 and Gly34 in Histone H3. Gene sequencing for histone was carried out by Sanger sequencing, which showed a Lysine (AAG) to methionine (ATA) substitution at codon 27 in Histone 3A (H3F3A) resulting in H3K27M mutation. Specific antibody against H3K27M mutation was not used. Integrated diagnosis of Diffuse midline glioma H3K27M (WHO grade 4) was made. The patient expired within a month following surgery.

Discussion
Adult brainstem gliomas account for <2% of the adult gliomas. Their radiographic appearance varies widely with
Fig. 1: MRI: T2 hyper intense. Infiltrative tumour 3x3x2cm extending to pineal region. Inferior to the splenium of corpus callosum and above the cerebellar hemispheres.

Fig. 2.a: Squash: Low grade glioma. (100x H&E), b: Nodular (Plexiform) architecture (100x, H&E), c: Low grade glial morphology with fibrillary background. (400x H&E), d: Moderate nuclear pleomorphism with few large nuclei and areas of calcification. (400x H&E)
Fig. 3: a: Loss of ATRX protein, b: Focal positivity for p53 protein, c: Low MIB-1 index (3-4%), d: IDH1R132H negative.

Fig. 4: H3K27M Mutation detected by Sanger sequencing.
Histones are protein components that are deposited during DNA synthesis. The nucleosome core is composed of an octamer of H2A, H2B, H3 & H4 and is linked to DNA via Histone H1. H3 has 3 isoforms 3.1, 3.2 & 3.3 which are important for transcription, telomerase activity and DNA repair. DMG typically shows Gain of function mutations in H3 Histone genes. Histone 3A (H3F3A) encodes histone H3 variant H3.3 and Histone H3B (HIST1H3B), encodes histone H3 variant H3.1. Histone H3.3 mutations occur at two distinct residues, either lysine at position 27 or glycine at position 34 resulting in replacement of lysine 27 by methionine (K27M) or replacement of glycine 34 by valine (G34V). Lysine to methionine substitution at codon 27 usually involves H3F3A but may also involve HIST1H3B/C genes (H3 K27M mutations) and is associated with aggressive diffuse midline gliomas.[8]

Severeral studies have reported that K27M mutant tumors are mostly seen in the midline structures whereas G34V mutant tumors occur in the cerebral hemispheres.[4,5] High grade gliomas associated with Histone H3.1 (HIST1H3B) mutations are seen predominantly in neonates and pediatrics, are usually located in the pontine location, associated with ACVR 1, OLIG1 & K2 mutations and have a median survival of 15 months. In contrast, Histone H3.3(H3F3A) associated gliomas can occur at any age, predominantly occur in any midline location, associated with TP53, DAXX & ATRX mutations and have a poor median survival of 9 months.[4,5]

Meyronet et al evaluated 21 adult patients with H3K27M mutant diffuse gliomas and found that all tumors had a midline location with 29% located in the spinal cord followed by 24% in the thalamus and 24% in the midbrain. Only 5% tumors were located in the pineal region as in our case. The clinical presentation was variable and consisted of progressive sensorimotor deficits (67%) followed by intracranial hypertension (29%), ataxia (24%) and cranial nerve injury (19%). On MRI, contrast enhancement was present in 50% of the cases. These diffuse gliomas had varied histomorphological features suggestive of a low grade glioma (15%) to glioblastoma multiforme (52%). 28% of the cases showed morphology that could not be categorized whereas pilocytic astrocytoma like features were noted in 2.5 % of the cases and 2.5 % showed ganglioglioma like features.[2] Pineal neoplasms are usually low grade astrocytomas and very few case reports of glioblastoma multiforme have been reported.[6] In our case too, low grade astrocytic tumor like pilocytic astrocytoma was considered as a differential on morphology.

Solomon et al studied 47 cases of Diffuse midline glioma H3K27M in both adult and pediatric patients and found that although a wide morphologic spectrum can be seen, all tumors show at least some classic astrocytic morphology characterized by ovoid to elongated nuclei with coarse chromatin and widespread oligodenrogial morphology is almost never seen. He reported histomorphology varying from gliomas with giant cells, epithelioid and rhabdoid cells, primitive neuroectodermal tumor (PNET)-like foci, neuropil-like islands, pilomyxoid features, ependymal-like areas, ganglionic differentiation to pleomorphic xanthoastrocytoma (PXA)-like areas. Majority of the tumors were centered in the pons, thalamus, and spinal cord, but a few were also located in the third ventricle, hypothalamus, pineal region and cerebellum.[7]

Schreck evaluated 163 cases of midline gliomas of which 15% had H3K27M mutation, of these only one case had high grade (III/IV) histomorphology, rest were all low grade, as was seen in our case. The most common locations for H3K27M mutated tumors were midbrain (67%), pons (36%) and cerebellum (25%). Also, there was no difference in the contrast enhancement on MRI between H3K27M mutant tumors and wild type tumors.[8]

Adult midline gliomas predominantly show H3K27M mutation. They are frequently associated with loss of ATRX (46.8%) and mutation of TP53(42.4%). They almost never show IDH1, EGFR, TERT and BRAF V 600E mutations.[7,8]

The median survival rate of these cases is 19.6 months as reported by Meyronet et al.[2] Recent reports have proposed that the survival of these cases may be similar or possibly improved as compared to gliomas with wild type mutation, however this needs further validation.[8]

Identification of this H3K27M mutation in diffuse midline gliomas is of utmost importance as it is has not only prognostic but also therapeutic significance. Various potential targeted treatment options are now under trial. Histone deacetylase inhibitor (HDACi), GSKJ4 has in-vitro and in-vivo anti-tumour activity against K27M mutant tumors. Vorinostat, a pan-HDACi has shown benefit in pre-clinical trials. Panobinostat (HDACi), has better activity than Vorinostat in-vitro. Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma (PBTC-047) is currently open.[9]

In order to diagnose DMG H3K27M mutant, a tumour should be diffuse, midline, a glioma and H3K27 M mutant, just presence of the mutation does not warranty a diagnosis of DMG(H3K27M) mutant.[10]
Conclusion
Diffuse midline glioma H3K27M mutant is a midline tumour that can have varied morphology on histopathology. Unlike other WHO grade IV tumours, it does not require the following criteria: atypia, mitosis, endothelial hyperplasia and necrosis for diagnosis. Any tumour with predominantly astrocytic differentiation and located in midline structures, should always be tested for H3K27M mutation.

Acknowledgements: Dr. Epari Sridhar, Tata memorial hospital, Mumbai for immunohistochemistry and genetic study

Funding
Nil

Competing Interests
Nil

References

*Corresponding author:
Dr. Sonal Paul, A-5/102, Chabhaiya Park, Kapurwadi, Thane (w)-400607
Phone: +91 9930856879
Email: sonalpaul1993@gmail.com

Financial or other Competing Interests: None.

Date of Submission : 11/05/2020
Date of Acceptance : 05/09/2020
Date of Publication : 30/10/2020